The TROPION-Breast02 trial is the first to show overall survival benefit in this patient population, indicating a potential ...
Raludotatug deruxtecan (R-DXd) received FDA breakthrough therapy designation for CDH6-expressing platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers. Phase 1 study demonstrated a ...
Trastuzumab deruxtecan (T-DXd) significantly improves IDFS over trastuzumab emtansine (T-DM1) in high-risk HER2-positive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback